Young women who undergo chemotherapy for cancer may face infertility. Our experiments are designed to learn how chemotherapy affects the ovaries. We propose to characterize murine ovarian mesenchymal stem cells and identify sub‐populations with enhanced differentiation capacity inside (multipotent) and outside (pluripotent) of the mesoderm. We would like to define these cells using single cell sequencing and characterize their regenerative capacity using a murine model of chemotherapy‐induced of ovarian dysfunction.

The goal of this proposal is to develop a new strategy for skeletal regeneration in patients who have osteogenesis imperfecta (OI) or brittle bone disease using epigenetics regulators that alter gene expression. We have shown that inhibiting a epigenetic regulator, PCR2, increases bone formation in normal mice and will determine if this also occurs in OI mice. We will also investigate if a small molecule that inhibits the PRC2 complex can also increase bone formation in OI mice and cells from OI patients.

We have developed a new technology to reprogram human cells to go back to a state from which they can then develop into other kinds of cells. Our technology is based on a strain of Measles virus, one of the safest vaccines in human history. In this project we will use modify our technology to correct genetic mutation in the human genome and particularly in patients with inherited red blood cell disorders, such as sickle cell disease.

This research tests a new product for patients who have had a heart attack (AMI, acute myeocardial infarction). This product would help protect and regenerate cells in a heart damaged by AMI.

Rion is a clinical‐phase regenerative medicine company based in Rochester, MN, focused on bringing novel regenerative technologies solving unmet medical needs of the people of Minnesota.